



## **XTCY Announces MCTO Status Update**

**Vancouver February 29, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy Therapeutics” or the “Company”)** today provides a bi-weekly default status update further to the Company's press release dated January 30, 2024 (the "**Announcement**") concerning the delay of the filing of its annual financial statements in respect of its year ended September 30, 2023, its management discussion and analysis relating to its annual financial statements, and the CEO and CFO certifications (collectively, the "**Required Documents**"), beyond the prescribed deadline of January 29, 2024.

As previously announced, the Company applied to the applicable Canadian securities' regulatory authorities for a voluntary management cease trade order ("**MCTO**"). The Company was granted the MCTO by the British Columbia Securities Commission.

The MCTO will stay in effect until the Required Documents are filed and the Company intends to satisfy the provisions of the alternative information guidelines in accordance with National Policy 12-203 - *Management Cease Trade Orders* ("**NP 12-203**") by issuing bi-weekly default status reports in the form of news releases until the situation is satisfactorily rectified.

The Company confirms that since the date of the Announcement, (a) other than as described herein, there have been no changes to the information contained in the Announcement that would reasonably be expected to be material to shareholders, (b) there have been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines as set out in NP 12-203, (c) there has not been any other subsequent specified default by the Company following the Announcement under NP 12-203, and (d) there is no other material information concerning the affairs of the Company that has not been generally disclosed.

The Company's management, together with its audit committee, has been working diligently with its auditor to provide all necessary information and complete the Required Documents. The Company confirms that it will continue to satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains delayed in filing the Required Documents.

### **About Xtacy Therapeutics Corp.:**

Xtacy Therapeutics Corp. is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

For further information visit websites: [www.xtacytherapeutics.com](http://www.xtacytherapeutics.com)

Or Contact Meris Kott CEO 604.484.0355 or email to [info@xtacytherapeutics.com](mailto:info@xtacytherapeutics.com)

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.